UiPath (NYSE:PATH) Given New $18.00 Price Target at JPMorgan Chase & Co.

UiPath (NYSE:PATH – Get Rating) had its price target raised by JPMorgan Chase & Co. from $16.00 to $18.00 in a report published on Thursday, Benzinga reports. The brokerage currently has a neutral rating on the healthcare company’s stock.

A number of other equities research analysts also recently weighed in on PATH. Royal Bank of Canada upped their price target on shares of UiPath from $15.00 to $17.00 in a report on Thursday. Credit Suisse Group reduced their price objective on shares of UiPath from $30.00 to $27.50 and set an outperform rating for the company in a research note on Wednesday, November 16th. Canaccord Genuity Group raised shares of UiPath from a hold rating to a buy rating and upped their price objective for the company from $14.50 to $19.00 in a research note on Thursday. Wells Fargo & Company upped their price objective on shares of UiPath from $16.00 to $18.00 and gave the company an overweight rating in a research note on Friday, December 2nd. Finally, Truist Financial reduced their price objective on shares of UiPath from $25.00 to $20.00 and set a buy rating for the company in a research note on Friday, December 2nd. Eight equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, UiPath currently has a consensus rating of Hold and a consensus target price of $19.19.

UiPath Price Performance

Shares of NYSE PATH opened at $17.05 on Thursday. UiPath has a twelve month low of $10.40 and a twelve month high of $31.88. The firm has a 50-day moving average of $15.06 and a two-hundred day moving average of $13.60.

Insider Transactions at UiPath

In other news, CFO Ashim Gupta sold 40,000 shares of the stock in a transaction that occurred on Wednesday, February 15th. The shares were sold at an average price of $16.61, for a total value of $664,400.00. Following the completion of the sale, the chief financial officer now directly owns 1,359,051 shares of the company’s stock, valued at $22,573,837.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 31.88% of the stock is owned by insiders.

Hedge Funds Weigh In On UiPath

Hedge funds have recently added to or reduced their stakes in the company. SeaCrest Wealth Management LLC acquired a new position in UiPath in the second quarter worth approximately $25,000. Householder Group Estate & Retirement Specialist LLC acquired a new position in UiPath in the third quarter worth approximately $25,000. Sonnipe Ltd acquired a new position in UiPath in the fourth quarter worth approximately $26,000. U.S. Capital Wealth Advisors LLC acquired a new position in UiPath in the fourth quarter worth approximately $26,000. Finally, Belpointe Asset Management LLC acquired a new position in UiPath in the fourth quarter worth approximately $27,000. Institutional investors and hedge funds own 56.40% of the company’s stock.

UiPath Company Profile

(Get Rating)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.